Conference Call Participants
Thomas Smith – Leerink Partners LLC, Research Division
Michael Yee – UBS Investment Bank, Research Division
Gavin Clark-Gartner – Evercore ISI Institutional Equities, Research Division
Alexander Thompson – Stifel, Nicolaus & Company, Incorporated, Research Division
Joseph Thome – TD Cowen, Research Division
Laura Chico – Wedbush Securities Inc., Research Division
Gregory Renza – Truist Securities, Inc., Research Division
Rami Katkhuda – LifeSci Capital, LLC, Research Division
Douglas Tsao – H.C. Wainwright & Co, LLC, Research Division
Lachlan Hanbury-Brown – William Blair & Company L.L.C., Research Division
Jin Law – Goldman Sachs Group, Inc., Research Division
Jacob Goell – Wells Fargo Securities, LLC, Research Division
Jason Butler – Citizens JMP Securities, LLC, Research Division
Brandon Frith – Wolfe Research, LLC
Serge Belanger – Needham & Company, LLC, Research Division
Lisa Walter – RBC Capital Markets, Research Division
Faisal Khurshid – Jefferies LLC, Research Division
Presentation
Operator
Good morning, ladies and gentlemen, and welcome to the Viridian Therapeutics conference call to review top line results from the REVEAL-1 Phase III clinical trial in active thyroid eye disease. [Operator Instructions] As a reminder, this conference call is being recorded.
I will now hand the call over to Greg Rossino, Senior Director of Investor Relations at Viridian. Please go ahead.
Greg Rossino
Thank you, Kate, and good morning, everyone. Thank you for joining us on our conference call to discuss the top line results from REVEAL-1, our Phase III clinical trial of Elegrobart in patients with active thyroid eye disease. You can access the press release and the slides for today’s call on the Investors page of our corporate website